Sex-specific cytokine signatures as predictors of anti-PD1 therapy response in non-small cell lung cancer
{{output}}
Background: The introduction of immune checkpoint inhibitors (ICI) as first-line therapy in the treatment of non-small cell lung cancer has dramatically improved response rates. However, more than half of NSCLC patients receiving... ...
